ZVRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Zevra Therapeutics Inc (ZVRA) is not a strong buy at the moment for a beginner investor with a long-term focus. While the stock shows some positive technical indicators and a bullish analyst rating, the lack of recent financial performance data, absence of significant trading trends, and no major news catalysts make it prudent to hold off for now. The investor's impatience and unwillingness to wait for optimal entry points further suggest that this is not the best immediate opportunity.
The MACD is positive and contracting, suggesting mild bullish momentum. RSI is neutral at 63.588, indicating no overbought or oversold conditions. Moving averages are bullish with SMA_5 > SMA_20 > SMA_200. Key support is at 10.919, and resistance is at 13.91. The stock is currently trading near its pivot level of 12.415.
Analyst Eddie Hickman from Guggenheim raised the price target to $25, citing growth potential from the GeneDx program, European market opportunities, and strong patient retention. The stock has bullish moving averages and a low put-call ratio in options data, indicating positive sentiment.
No significant news or event-driven catalysts in the recent week. Hedge funds and insiders remain neutral with no notable trading trends. Congress trading data is unavailable, and financial performance data for the latest quarter is missing.
No financial performance data is available for analysis due to data error.
Guggenheim maintains a Buy rating and raised the price target from $23 to $25, highlighting growth potential in key programs and markets.
